Table 1.
Baseline clinical and demographic information
| Total sample (N = 1051) | |
|---|---|
| Age (years) | 73.7 (6.8) |
| Sex (n, % female) | 455 (43.3%) |
| Education (years) | 16.0 (2.8) |
| APOE ϵ4 carriers (n, %) | 437 (41.6%) |
| MCI (n, %) | 680 (64.7%) |
| Aβ (n, % abnormal) | 438 (41.7%) |
| Ptau (n, % abnormal) | 431 (41.0%) |
| MMSE score | 28.1 (1.7) |
| CDR-sb score | 0.96 (0.96) |
| BMI (kg/m2) | 27.0 (4.5) |
| Vascular risk (n, % low) | 978 (93.1%) |
| Medication use (n, %) | |
| Antihypertensive agents | 439 (41.8%) |
| ACE inhibitors | 181 (17.2%) |
| ARBs | 96 (9.1%) |
| Alpha blockers | 24 (2.3%) |
| Calcium channel blockers | 82 (7.8%) |
| Diuretics | 56 (5.3%) |
| Antidementia agents | 398 (37.9%) |
| Systolic BP (mmHg) | |
| Baseline | 134.6 (16.9) |
| Average | 133.2 (13.5) |
| VIM | 5.3 (3.6) |
| Diastolic BP (mmHg) | |
| Baseline | 74.6 (9.8) |
| Average | 73.6 (7.8) |
| VIM | 5.9 (1.2) |
Means and SDs shown unless otherwise indicated
MMSE, Mini Mental State Exam; BP, blood pressure; BMI, body mass index: VIM, variability independent of mean; APOE ϵ4, apolipoprotein ϵ4; MCI, mild cognitive impairment; CDR-sb, Clinical Dementia Rating Scale sum of box score; Aβ, amyloid-beta; Ptau, phosphorylated tau; ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers